201 related articles for article (PubMed ID: 28212922)
21. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
22. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application.
Guo Y; Sawalha AH; Lu Q
Clin Immunol; 2014 Nov; 155(1):79-90. PubMed ID: 25218424
[TBL] [Abstract][Full Text] [Related]
24. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus.
Yu H; Nagafuchi Y; Fujio K
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206696
[TBL] [Abstract][Full Text] [Related]
25. Translating epigenetics into clinic: focus on lupus.
Wang Z; Chang C; Peng M; Lu Q
Clin Epigenetics; 2017; 9():78. PubMed ID: 28785369
[TBL] [Abstract][Full Text] [Related]
26. [Systemic lupus erythematosus and pregnancy].
Szczepańiska M; Muszewska E; Szprynger K; Niwińska-Faryna B
Wiad Lek; 2008; 61(4-6):161-5. PubMed ID: 18939368
[TBL] [Abstract][Full Text] [Related]
27. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry.
Goulielmos GN; Zervou MI; Vazgiourakis VM; Ghodke-Puranik Y; Garyfallos A; Niewold TB
Gene; 2018 Aug; 668():59-72. PubMed ID: 29775752
[TBL] [Abstract][Full Text] [Related]
28. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
29. New directions in the treatment of systemic lupus erythematosus.
Kalunian K; Merrill JT
Curr Med Res Opin; 2009 Jun; 25(6):1501-14. PubMed ID: 19435401
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic dysregulation in systemic lupus erythematosus.
Liu A; La Cava A
Autoimmunity; 2014 Jun; 47(4):215-9. PubMed ID: 24128164
[TBL] [Abstract][Full Text] [Related]
31. Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.
Tan G; Baby B; Zhou Y; Wu T
Front Immunol; 2021; 12():808839. PubMed ID: 35095896
[TBL] [Abstract][Full Text] [Related]
32. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
[TBL] [Abstract][Full Text] [Related]
33. Progress in the application of body fluid and tissue level mRNAs-non-coding RNAs for the early diagnosis and prognostic evaluation of systemic lupus erythematosus.
Liang J; Xie F; Feng J; Huang C; Shen J; Han Z; Luo W; He J; Chen H
Front Immunol; 2022; 13():1020891. PubMed ID: 36325322
[TBL] [Abstract][Full Text] [Related]
34. IFN-γ, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus.
Wen S; He F; Zhu X; Yuan S; Liu H; Sun L
Clin Exp Rheumatol; 2018; 36(1):36-43. PubMed ID: 28628472
[TBL] [Abstract][Full Text] [Related]
35. The applied basic research of systemic lupus erythematosus based on the biological omics.
Sui W; Hou X; Che W; Yang M; Dai Y
Genes Immun; 2013 Apr; 14(3):133-46. PubMed ID: 23446742
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Ruiz-Irastorza G; Danza A; Khamashta M
Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
[TBL] [Abstract][Full Text] [Related]
37. Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers.
Dumestre-Pérard C; Clavarino G; Colliard S; Cesbron JY; Thielens NM
Autoimmun Rev; 2018 Sep; 17(9):890-899. PubMed ID: 30009962
[TBL] [Abstract][Full Text] [Related]
38. From old concerns to new advances and personalized medicine in lupus: The end of the tunnel is approaching.
Doria A; Gershwin ME; Selmi C
J Autoimmun; 2016 Nov; 74():1-5. PubMed ID: 27592380
[TBL] [Abstract][Full Text] [Related]
39. [Systemic lupus erythematosus in children and adolescents].
Sallmann S; Fiebig B; Hedrich CM; Heubner G; Gahr M
Z Rheumatol; 2006 Nov; 65(7):576-8, 580-2, 584-5. PubMed ID: 17072573
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus.
Cigni A; Pileri PV; Faedda R; Gallo P; Sini A; Satta AE; Marras R; Carta E; Argiolas D; Rum I; Masala A
J Investig Med; 2014 Jun; 62(5):825-9. PubMed ID: 24987977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
